Tag Archive for: life sciences

Sofinnova Partners closes €725M Crossover II Fund

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets.   PARIS, France – November 16, 2026 – Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, […]

Sector updates in October

  Investment funds  Orbimed secured $3 billion across two new funds, OrbiMed Private Investments X and OrbiMed Asia Partners VI, to build leading healthcare companies   Forbion secured €2.3 billion across two new funds, Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, to invest in high potential biotechs  TCGX secured $600 million for its […]

Optimum Strategic Communications to Host 18th Annual Healthcare Investor Conference

“Maximising Europe’s Potential” will put capital, scale and patient impact centre stage London, UK, 6 October 2026: Optimum Strategic Communications (Optimum), the specialist life sciences communications consultancy, will host its 18th invitation-only Annual Healthcare Investor Conference on Thursday 8 October 2026 at The King’s Fund, Cavendish Square, London. Under the theme “Maximising Europe’s Potential”, leaders […]

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026 Barcelona, Spain and Düsseldorf, Germany – 25 September, 2026 – Neuraxpharm Group and Minoryx Therapeutics, today announce that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), an […]

Weekly Roundup: Transformative tech at ON Helix 2026

Sofinnova Partners announced Myricx Bio agrees to be acquired by Novartis Sofinnova Partners, a leading European life sciences venture capital firm, announced that its portfolio company Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion cash upfront plus potential milestone payments. Sofinnova Partners seeded the […]

© Optimum Strategic Communications.